Book contents
- Bipolar II Disorder
- Bipolar II Disorder
- Copyright page
- Dedication
- Contents
- Contributors
- Preface to the Third Edition
- Acknowledgements
- Section 1 Domain Chapters
- Section 2 Management Commentaries
- 18 Introduction to Management Commentaries
- 19 Management Commentary
- 20 Management Commentary
- 21 Management Commentary
- 22 Management Commentary
- 23 Management Commentary
- 24 Management Commentary
- 25 Management Commentary
- 26 Management Commentary
- 27 Management Commentary
- 28 Management Commentary
- 29 Management Commentary
- 30 Management Commentary
- 31 Management Commentary
- 32 Management Commentary
- 33 Management commentary
- 34 Management Commentary
- 35 Management Commentary
- 36 Management Commentary
- Section 3 Conclusion
- Index
- References
36 - Management Commentary
from Section 2 - Management Commentaries
Published online by Cambridge University Press: 17 December 2018
By
Edited by
Book contents
- Bipolar II Disorder
- Bipolar II Disorder
- Copyright page
- Dedication
- Contents
- Contributors
- Preface to the Third Edition
- Acknowledgements
- Section 1 Domain Chapters
- Section 2 Management Commentaries
- 18 Introduction to Management Commentaries
- 19 Management Commentary
- 20 Management Commentary
- 21 Management Commentary
- 22 Management Commentary
- 23 Management Commentary
- 24 Management Commentary
- 25 Management Commentary
- 26 Management Commentary
- 27 Management Commentary
- 28 Management Commentary
- 29 Management Commentary
- 30 Management Commentary
- 31 Management Commentary
- 32 Management Commentary
- 33 Management commentary
- 34 Management Commentary
- 35 Management Commentary
- 36 Management Commentary
- Section 3 Conclusion
- Index
- References
- Type
- Chapter
- Information
- Bipolar II DisorderModelling, Measuring and Managing, pp. 285 - 288Publisher: Cambridge University PressPrint publication year: 2019
References
Azorin, J. M., Sapin, C. and Weiller, E. (2013). Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. Journal of Affective Disorders, 145, 62–9.Google Scholar
Cuomo, A., Nikolova, V. L., Yalin, N. et al. (2017). Pharmacological treatment of mixed states. CNS Spectrums, 22, 186–95.Google Scholar
Franks, M. A., Macritchie, K. A. N., Mahmood, T. et al. (2008). Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. Journal of Psychopharmacology, 22, 452–6.CrossRefGoogle ScholarPubMed
Merikangas, K. R. and Lamers, F. (2012). The ‘true’ prevalence of bipolar II disorder. Current Opinion in Psychiatry, 25, 19–23.Google Scholar
McElroy, S. L., Weisler, R. H., Chang, W. et al. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression. Journal of Clinical Psychiatry, 71, 163.Google Scholar
Young, A. H., Calabrese, J. R., Gustafsson, U. et al. (2013). Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. International Journal of Bipolar Disorders, 1, 10.Google Scholar
- 1
- Cited by